ERBB2 and breast carcinoma: While trastuzumab has been used in the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer, several studies have focused on its effectiveness on patients with HER2-positive GC due to the 8.2–15.6% positivity of HER2 expression status [8–10].